Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | NQO2 | P16083 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757192 | 0.94 | AKR1B1 (0.46) | AKR1B1CYP19A1NQO2ALDH1A1MAPT | |
| SCHEMBL2622281 | 0.84 | AKR1B1 (0.38) | AKR1B1CYP19A1NQO2MAPTCYP3A4 | |
| SCHEMBL12664485 | 0.83 | AKR1B1 (0.43) | AKR1B1CYP19A1NQO2ALDH1A1MAPT | |
| SCHEMBL12673575 | 0.80 | ALDH1A1 (0.42) | AKR1B1CYP19A1NQO2ALDH1A1MAPT | |
| SCHEMBL13917719 | 0.74 | AKR1B1 (0.40) | AKR1B1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL353909 | 0.73 | MEN1 (0.43) | AKR1B1CYP19A1NQO2ALDH1A1MAPT | |
| SCHEMBL11304210 | 0.72 | ALDH1A1 (0.54) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL2622282 | 0.72 | PDE3B (0.43) | AKR1B1CYP19A1NQO2ALDH1A1MAPT | |
| SCHEMBL353813 | 0.72 | AKR1B1 (0.51) | AKR1B1CYP19A1NQO2MAPTCYP3A4 | |
| SCHEMBL677316 | 0.72 | CYP19A1 (0.46) | AKR1B1CYP19A1NQO2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205088-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RES (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9115061-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115061-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-25 | — | — | US | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039668-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112112-A1 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | CYP17A1, HSD17B7, CYP27A1 | AKR1B1 66/4885CYP19A1 33/4885NQO2 1578/4885 |
| US-20100267781-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | AKR1B1 1345/4885CYP19A1 2620/4885NQO2 541/4885 |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | AKR1B1 1140/4885CYP19A1 2483/4885NQO2 646/4885 |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | BCL3, BCL9, BCL2 | AKR1B1 1203/4885CYP19A1 550/4885NQO2 4269/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | AKR1B1 1341/4885CYP19A1 2008/4885NQO2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.